Treatment Of Inflammatory Lesions Research Articles

The use of light in the treatment of acne vulgaris-a review.

Topical and oral antibiotic therapy is also a popular method of treatment. The effectiveness of this method is limited by the increasing resistance of bacteria to antibiotics. Over the decades since the introduction of antibiotics to treat acne, the resistance levels of bacteria have changed. This defense mechanism is developed evolutionarily. Modifications of antibiotic receptor sites, alteration of drug influx/efflux, or enzymatic degradation are common mechanisms used by bacteria to initiate and strengthen internal antibiotic resistance. The basic chromophores used in light therapy are hemoglobin, melanin, water bound to proteins, and porphyrins. Hemoglobin absorbs light mainly at 580nm, while melanin absorbs the entire visible spectral range (400-750nm). Porphyrins are aromatic compounds, classified as photosensitizing substances, intensively absorbing blue light, and to a lesser extent in long visible bands, such as orange and red light. Using IPL makes it possible to cover the maximum light absorption of porphyrins and hemoglobin, therefore it can be an effective tool in the treatment of inflammatory lesions in acne vulgaris. In view of the effectiveness of light therapy and its effect even on antibiotic-resistant bacteria, it is worth considering the possibility of using light therapy instead of antibiotic therapy. Due to the increasing resistance of bacteria to antimicrobials, they should be used with caution and as a last resort. The high-energy light treatment act only locally (unlike with antibiotics taken orally) and on a chromophore, such as melanin, hemoglobin, or porphyrins.

577-nm high-power optically pumped semiconductor laser is safe and effective in the treatment of inflammatory acne: a prospective, single-center, split-face comparative study

ObjectiveThis study aimed to appraise the efficacy of a 577-nm high-power optically pumped semiconductor laser (HOPSL) for the treatment of inflammatory acne.MethodsThe study included 50 patients with acne vulgaris (inflammatory type), 14 men, and 36 women; patient ages ranged from 16 to 35 years. The left side of the face was treated with a single pass of a 577-nm high-power optically pumped semiconductor laser (HOPSL) every 2 weeks for 3 sessions. The severity of acne examined prior to the first session and 4 weeks after the last session (Investigator's Global Assessment of acne severity, IGA; single lesion count).ResultsAt baseline, no statistically significant difference in the severity of inflammatory acne lesions between both sides was observed. One month after the final session, a significant improvement (IGA reduction of > 50%) of the overall severity of acne was observed in 49 patients (98%) on the laser-treated side versus 41 (82%) the control side of the face (P < .05). Hence, we found a significant reduction in the mean percentage of inflammatory papules, pustules, and nodules on the laser-treated versus the control side (79.33 vs 56.92, 78.04 vs 43.33, 64.85 vs 21.93%, respectively) (P < 0.05). Side effects in the form of erythema and irritation during sessions were transient and tolerated by the patients.ConclusionThe 577-nm high-power optically pumped semiconductor laser is effective and safe for the treatment of inflammatory lesions (papules, pustules, and nodules) in acne patients.

The immunomodulatory potential of Leonurus cardiaca extract in relation to endothelial cells and platelets.

The immunomodulatory activity of Leonurus cardiaca L. polyphenol-rich extract (LCE) was tested invitro on HUVECs to explore its potential therapeutic usefulness in the treatment of inflammatory lesions. The phytochemical composition of LCE, its antioxidant and cytotoxic activity, and the influence of LCE on NO and platelet-activating factor (PAF) secretion by HUVECs and platelet aggregation were all assessed. Total polyphenol contents in LCE reached 137.0 ± 0.8 mg/g, with hydroxycinnamic acid derivatives as the predominant phenolic compounds. LCE expressed antioxidant capacity, which was, however, 13- to 16-fold lower than the antioxidant activity of ascorbic acid. The plant extract was not cytotoxic up to a concentration 4500 µg/ml and did not exhibit proapoptotic activity. LCE significantly increased NO production in HUVECs in a concentration-dependent manner and led to the inhibition of PAF secretion induced by staphylococcal peptidoglycan. The extract used at the concentration of 100 µg/ml significantly reduced platelet aggregation in the presence of arachidonic acid. We provide invitro data demonstrating the immunomodulatory potential of LCE, which may be beneficial in preventing the development of difficult-to-treat inflammatory lesions within chronically infected tissues.

Magnetoledoterapia w leczeniu zmian zapalnych i nadżerkowych żołędzi – opis przypadku

ENWEndNote BIBJabRef, Mendeley RISPapers, Reference Manager, RefWorks, Zotero AMA Pasek J, Pasek T, Cieślar G, Sieroń A. Magneto-LED therapy in the treatment of inflammatory lesions and erosions of the glans penis – case report. Dermatology Review/Przegląd Dermatologiczny. 2016;103(5):367-370. doi:10.5114/dr.2016.62887. APA Pasek, J., Pasek, T., Cieślar, G., & Sieroń, A. (2016). Magneto-LED therapy in the treatment of inflammatory lesions and erosions of the glans penis – case report. Dermatology Review/Przegląd Dermatologiczny, 103(5), 367-370. https://doi.org/10.5114/dr.2016.62887 Chicago Pasek, Jarosław, Tomasz Pasek, Grzegorz Cieślar, and Aleksander Sieroń. 2016. "Magneto-LED therapy in the treatment of inflammatory lesions and erosions of the glans penis – case report". Dermatology Review/Przegląd Dermatologiczny 103 (5): 367-370. doi:10.5114/dr.2016.62887. Harvard Pasek, J., Pasek, T., Cieślar, G., and Sieroń, A. (2016). Magneto-LED therapy in the treatment of inflammatory lesions and erosions of the glans penis – case report. Dermatology Review/Przegląd Dermatologiczny, 103(5), pp.367-370. https://doi.org/10.5114/dr.2016.62887 MLA Pasek, Jarosław et al. "Magneto-LED therapy in the treatment of inflammatory lesions and erosions of the glans penis – case report." Dermatology Review/Przegląd Dermatologiczny, vol. 103, no. 5, 2016, pp. 367-370. doi:10.5114/dr.2016.62887. Vancouver Pasek J, Pasek T, Cieślar G, Sieroń A. Magneto-LED therapy in the treatment of inflammatory lesions and erosions of the glans penis – case report. Dermatology Review/Przegląd Dermatologiczny. 2016;103(5):367-370. doi:10.5114/dr.2016.62887.

POSSIBILITIES EFFECTIVE REGENERATION OF PERIODONTAL TISSUES DURING TOPICAL TREATMENT OF CHITOSAN

The article shows the results of an experimental morphological study of the efficiency of various compounds of chitosan for the treatment of inflammatory lesions of destructive periodontal tissues. Objective: to study the effectiveness of the treatment of periodontal tissue destructive lesions in the application of chitosan. Objectives : To evaluate the morphological changes in the tissues after treatment of chronic apical periodontitis with chitosan and zinc oxide paste to evaluate the morphological changes in the tissues, resulting in the treatment of chronic generalized periodontitis and diabetes mellitus type I, using a gel composition of chitosan- alginate - hydroxyapatite. Materials and Methods : A morphological study of dog periodontal micropreparations with chronic apical periodontitis model and rat micropreparations model of insulin-dependent diabetes mellitus and chronic generalized periodontitis treated with the use of chitosan products. As a result of the morphological study found that chitozan containing compositions used as the material for the treatment of anti-inflammatory action and actively stimulate reparative processes as periodontal soft tissues and periodontal and vascular and alveolar bone region of the experimental animals. Scope results : medicine, dentistry

Über die Wirkung von (Schwarz-) Teeumschlägen auf die Haut

SummaryMillennia-old experience with application of tea extracts as an external treatment prove beneficial in the treatment of inflammatory lesions of various origins, in particular but also in the context of venous disorders. The legends that abound in the discovery of tea are innumerable. One tells of how a coincidence the Chinese Emperor Shen Nung (2737 BC), who took great care to ensure cleanliness and cooked for this reason his drinking water, the tea flavour brought: A gust of wind blew some tea leaves into the kettle with boiling water, this golden colored it and gave him a pleasant aroma. The emperor tasted the drink and felt refreshed. Tea was then the drink in the „Middle Kingdom“, just as long – but probably even longer – it is used there as a remedy. Later in the Tang Dynasty (618–907 AD) tea was discovered as a commodity, and it developed into a vibrant China's tea trade with its neighbors, this time the tea was probably also brought about by land to Europe. A wide distribution in the population took place in Europe but only after the first tea transport from Japan to Amsterdam with sailboats in 1610. The application of (herbal) tea extracts in the context of compresses for the treatment of skin diseases was embedded in the population in Europe but much earlier. So this is described in the books of Hildegard von Bingen (*1098; † September 17, 1179). Nowadays, the application of black tea extract in the topical treatment of inflammatory and infectious diseases in traditional medicine is widespread and established in dermatology, paediatrics, combustion medicine, radiotherapy, gynaecology and allergology.The beneficial in the treatment of inflammatory lesions applies also to skin affections in the context of venous disorders. This could be demonstrated here in a not placebo controlled, non-randomized study: The treatment of 40 patients with inflammatory skin changes at the lower legs, mostly in the context of venous disorders, with black tea compresses started on the first day of patient contact and was always carried out in addition to a causal treatment of the underlying disease. In no case there was a worsening of the findings. In all cases a fast decay of redness, oozing, erosion, itching, pain, tenderness and edema within 2 to 3 days was observed after initiation of treatment.An analysis of the evidence for the mechanisms of action by review of the extensive literature shows that well-founded knowledge on anti-inflammatory, antimicrobial, analgesic, anticancer, differentiation-promoting and antiaging properties is available. A detailed description of the pathophysiologic findings on the various effects is thus given. Conclusion: The good tolerability of this treatment combined with good effect, especially in combination with other therapies and the experience of probably millions of people for many centuries is a recommendation to apply this treatment more frequently, particularly as an adjunctive treatment of inflammatory lesions. The findings on the protective effects against chemical, physical and microbial aggressions mean that tea extracts can be potent agents in the prevention of skin diseases in the context of chemical loads in the (working) life, of natural and unnatural radiation exposure and in people with a tendency for inflammatory skin diseases such as eczema appear to seborrheic dermatitis, psoriasis or vitiligo. Moreover, there is evidence that tea extracts are able to stop the skin aging process, not only, but even reverse it. All these arguments are sufficient as a reason for a more frequent use of tea and tea extracts in the treatment and prevention of skin diseases.Treatment protocol: Preparation of tea compresses: Take tea bags individually or 4 in 500 ml of water or 5 teaspoons tea leaves ~ 10 g tea leaves in 500 ml water. Bring water to boil. Pour tea leaves / tea bags with hot water and wait more than 10 (to 30) minutes, strain tea leaves, remove bags, cool tea and tea bags (e. g. in a refrigerator at 8° C). Application of tea compresses: Put cool, damp (not dripping-wet) tea bags of affected skin or for larger affectes skin areas soak ironed handkerchief or cotton cloth with cold tea and put it cool, damp (not dripping-wet) to the affected skin, e. g. wrap the affected extremity. Do not forget to put inferior to it an old towel or paper for tea stains strongly yellow-brown! Leave tea bags or tea compresses for 5 to 15 min to take effect. Repeat treatment 2–3x/day until acute symptoms are relieved or disappeared.

Tretinoin gel microspheres 0.04% versus 0.1% in adolescents and adults with mild to moderate acne vulgaris: A 12-week, multicenter, randomized, double-blind, parallel-group, phase IV trial

Topical retinoids are considered first-line therapy in the treatment of acne vulgaris, yet can be associated with cutaneous irritation, including erythema, peeling, dryness, burning, and itching. Tretinoin gel microsphere (TGM) formulations were developed to minimize these effects. A lower-strength TGM formulation may be desirable to further reduce exposure to tretinoin. This study was conducted to assess the efficacy and safety profile of a lower-dose TGM (0.04%) formulation compared with TGM 0.1% for the treatment of mild to moderate acne vulgaris. In this multicenter, double-blind, parallel-group, Phase IV dose-ranging study, patients with facial acne were randomized to apply either TGM 0.04% or TGM 0.1% to the face each night for 12 weeks. Patients must have discontinued systemic retinoid treatment for at least 1 year before the study and were not to have used any topical retinoids, systemic antibiotics, nicotinamide, or systemic steroids for at least 1 month. All other topical medications applied to the face (including corticosteroids, antimicrobials, salicylic acid, and benzoyl peroxide) were to be discontinued at least 2 weeks before the study. End points were the acne lesion count (total, inflammatory, and noninflammatory lesions) and the investigators' and patients' assessments of improvement. Adverse events (including severity and relationship to treatment) and signs and symptoms of cutaneous irritation at the treatment site were monitored at each study visit. One hundred fifty-six patients (78 TGM 0.04%, 78 TGM 0.1%) were randomized and received treatment. Patients ranged in age from 12 to 41 years (mean, 18.4 years) and were predominantly white (n = 89 [57.1%]) and male (n = 80 [51.3%]). Both TGM 0.04% and TGM 0.1% were associated with a reduction from baseline in total, inflammatory, and noninflammatory lesions. The differences between groups in the change in lesion counts from baseline to weeks 2, 4, 8, and 12 were not statistically significant. However, there was a greater reduction in inflammatory lesions at week 2 for TGM 0.1% compared with TGM 0.04% (14.8% vs 6.0%, respectively; P < 0.047). Both treatment groups had similar improvements in the investigators' global evaluation and the patients' assessment of the response to treatment. Both TGM 0.04% and TGM 0.1% were well tolerated. The most common adverse events were skin-associated burning sensation (2.6% in the TGM 0.04% group and 7.7% in the TGM 0.1% group) and irritation (6.4% and 3.8%, respectively). In the TGM 0.04% group, significantly fewer patients experienced dryness of the treatment area during the early phase of treatment (P < 0.027). However, for other measures of cutaneous irritation (peeling, burning/stinging, and itching), either there were no statistically significant differences between treatment groups or, in the case of erythema, there was a significant difference in favor of TGM 0.1% (P = 0.035). Both TGM 0.04% and TGM 0.1% were associated with reductions in lesion counts in these patients with mild to moderate facial acne. Both concentrations were generally well tolerated. The results suggested an early (week 2) incremental benefit for the use of TGM 0.1% in the treatment of inflammatory lesions.

Prostaglandin Production by Human Gingival Fibroblasts Inhibited by Triclosan in the Presence of Cetylpyridinium Chloride

The effect of triclosan plus the cationic detergent cetylpyridinium chloride (CPC) was evaluated for prostaglandin inhibition in human gingival fibroblasts. Since triclosan has previously been shown to inhibit proinflammatory cytokine induced prostaglandin E2 (PGE2) production, we wanted to determine if triclosan, in the presence of CPC, could enhance these effects. Initial studies determined that both triclosan and CPC were cytotoxic to human gingival fibroblasts in concentrations exceeding 1.0 microg/ml for either agent longer than 24 hours in a tissue culture. Therefore, subsequent studies measuring prostaglandin biosynthesis and cyclooxygenase (COX)-1 and COX-2 mRNA expression were performed in concentrations and times that did not significantly affect cell viability. PGE2 biosynthesis was dose dependently inhibited by both triclosan and triclosan and CPC when challenged by tumor necrosis factor (TNF)-alpha or interleukin (IL)-1beta. At pharmacologically relevant concentrations, triclosan and CPC inhibited IL-1beta-induced PGE2 production to a greater extent than triclosan alone (P = 0.02). Moreover, enhanced COX-2 mRNA repression was observed with triclosan and CPC in comparison to triclosan alone in IL-1beta and TNF-alpha stimulated cells. No effect on COX-1 gene expression was observed. Further analysis of cell signaling mechanisms of triclosan and CPC indicates that nuclear factor-kappa B (NF-kappaB) and not p38 mitogen-activated protein kinase (MAPK) signaling may be impaired in the presence of triclosan and CPC. This study indicates that triclosan and CPC are more effective at inhibiting PGE2 at the level of COX-2 gene regulation, and this combination may offer a potentially better anti-inflammatory agent in the treatment of inflammatory lesions in the oral cavity.

A New Method of Treatment of Inflammatory Lesions of the Female Urethra

The female urethra is the homologue of the posterior urethra of the male. Vestigial remnants of the prostatic ducts and glands are part of the anatomy of the normal female urethra. These structures are predisposed to infection, both acute and chronic. A simple and successful method of treatment is aimed at complete eradication of the responsible primarily infected paraurethral ducts and glands and the dependent secondary pathologic changes of contiguous structures. Symptomatic relief, elimination of infection, and absence of recurrence in 206 patients have been impressive.

The Action of Roentgen Rays on Inflammatory Conditions

During the past fifteen years, an increasing number of radiologists and other physicians have become interested in roentgen therapy for inflammatory conditions. Some chronic inflammations, notably of the skin and lymph nodes, had been treated with roentgen rays as early as 1896 and 1897, but this had been done empirically. Early trials of roentgen therapy for chronic inflammations were made in this country, but it is only true to say that some of these attempts were not systematically followed up and often they were unknown to all but a few. As for the treatment of acute inflammations, much of this was first carried out in various European countries, and American radiologists have been a little slow in following the lead. It was only after the World War that the treatment of chronic and especially of acute conditions became an established procedure. This was due to the work of many physicians, but special credit is due Heidenhain and Fried,2 who treated in this manner a large number of different kinds of inflammation. Their reports have had a greater influence, perhaps, in stimulating the use of roentgen rays in the treatment of inflammations than those of any other medical writers. There is no longer any doubt that roentgen rays often have a beneficial effect on many varieties of acute and chronic inflammation. The evidence is now so abundant that it cannot be disregarded. It has been difficult for internists and surgeons, and for some radiologists also, to understand how an agent which has been used so largely to treat malignant tumors can also be an effective means of treating acute or chronic inflammatory processes. In malignant neoplasms, the rays act mainly by destroying malignant cells. How can this be reconciled with the treatment of inflammatory lesions? One reason for this difficulty is that so few physicians have been familiar with the experimental background of roentgen therapy and with the sensitiveness of different kinds of tissue and cells to the rays. A second reason is the great variety of inflammations for which the therapeutic value of roentgen rays has been claimed, and the lack of a convincing explanation of the action of the rays on these many different conditions. Still another reason for the hesitation of internists and surgeons to take advantage of this method of treatment for the benefit of their patients has been the fear of deleterious changes such as are not infrequently observed following the treatment of malignant tumors. In 1931 I attempted to explain the action of the rays on acute and chronic inflammations. This explanation was based on a knowledge of the results of many experiments on animals and of the large number of clinical observations to be found in the medical publications of different countries over many years.

Radiation Therapy in the Treatment of Inflammatory Lesions

Radiation Therapy in the Treatment of Inflammatory Lesions